[CAS NO. 1312991-76-6] Ro25-6981Maleate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1312991-76-6]

Catalog

AS962194

Brand

Arctom Scientific

CAS

1312991-76-6

DESCRIPTION [1312991-76-6]

Overview

MDL	-
Molecular Weight	455.54
Molecular Formula	C26H33NO6
SMILES	OC1=CC=C([C@H](O)[C@@H](C)CN2CCC(CC3=CC=CC=C3)CC2)C=C1.O=C(O)/C=C\C(O)=O

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) ^[1] ^[2] ^[3] .

In Vivo

Ro 25-6981 Maleate (0.39-12.5 mg/kg; i.p.) induces contraversive rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats without stimulating locomotion in normal rats ^[1] .
Ro 25-6981 Maleate (1,3 mg/kg; i.p.) exhibits age- and activation-dependent anticonvulsant action at early postnatal development in rats ^[2] .
Ro 25-6981 Maleate (800 µg; intrathecal injection) shows significant analgesic effects on incision pain in rats and effectively attenuated postoperative hyperalgesia induced by remifentanil ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-OHDA-lesioned rats ^[1]
Dosage:	0.39-12.5 mg/kg
Administration:	I.p.
Result:	Dose-dependently induced contraversive tight nose-to-tail rotations, and induced a weak ipsiversive circling response indicating a mild unspecific stimulatory action of the compound.

Animal Model:	Male albino rats of Wistar strain ^[2]
Dosage:	1, 3 mg/kg
Administration:	I.p.
Result:	Caused a significant decrease of N1–P2 amplitude at higher stimulation intensities AT 3 mg/kg, and exhibited age- and activation-dependent anticonvulsant action at early postnatal development.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 219.52 mM ; Need ultrasonic)

H ₂ O : 8.33 mg/mL ( 18.29 mM ; ultrasonic and warming and heat to 45°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1952 mL	10.9760 mL	21.9520 mL
5 mM	0.4390 mL	2.1952 mL	4.3904 mL
10 mM	0.2195 mL	1.0976 mL	2.1952 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 5 mg/mL (10.98 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 5 mg/mL (10.98 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 5 mg/mL (10.98 mM); Clear solution

* All of the co-solvents are available by MCE.